Targets › INTS8
1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Mar 2028.
Component of the integrator complex, a multiprotein complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes. The integrator complex provides a quality checkpoint during transcription elongation by driving premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation: the complex terminates transcription by (1)…. (UniProt, Q75QN2)
Open in Phaseline: the race on INTS8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gilead Sciences | Islatravir Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | RT, IN, POLB, INTS1, INTS8 | Phase 3 | HIV-1-Infection; HIV-1-infection; HIV-1 Infection | Mar 2028 |
HIV-1-Infection (1) HIV-1-infection (1) HIV-1 Infection (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.